Private Valuation & Funding Round Tracker · Huma

Huma funding rounds & valuation history

Name: Huma Funding Rounds & Valuation History
Creator: growthnavigatefunding.net

Huma Therapeutics (formerly Medopad, renamed 2020), the London healthcare-AI and digital-health platform company founded by Dan Vahdat. Funding from the Series B (as Medopad) to the Strategic investment (Eckuity Capital), sourced to Huma, Bloomberg, Huma via PR Newswire and TechCrunch.

Last updated: 13 Nov 2026 (IST). Every figure re-checked against the linked sources that day. Rows: 4 Currency: US$, nominal

⬇ Download CSV Cite this dataset Methodology & status definitions

Last closed round Closed

Undisclosed amount

Undisclosed amount Strategic investment (Eckuity Capital)

Raised in rounds listed

$205M

Sum of 3 closed rounds with a disclosed amount (GNF calc.)

Largest round

$100M equity (of $130M)

Series C, May 2021

Closed rounds listed

Nov 2019 to May 2025

Round history

Newest first. Dashed badges and striped rows are not closed transactions. “—” means the source does not disclose the figure or it cannot be computed on the same basis; see the note in each row.

Huma funding rounds, Nov 2019 to May 2025
Date	Status	Round	Amount	Lead / buyer	Valuation	Val. ÷ run-rate	Source
16 May 2025	Closed round	Strategic investment (Eckuity Capital)Amount not disclosed. Announced together with Huma’s acquisition of Aluna and an M&A-focused partnership.	—Not disclosed	Eckuity Capital	Not disclosedNo company valuation stated by the source	—Not disclosedNo run-rate stated in the announcement	Huma, 16 May 2025
16 Jul 2024	Closed round	Series DHuma’s “over $80m” share issuance includes strategic investments made since the Series C. $80M is used as a floor.	Over $80M	—Not disclosedWith: AstraZeneca, HAT Technology Fund 4, Hitachi Ventures, Leaps by Bayer	Near $1B (reported)Bloomberg headline (“near-$1 billion valuation”); not stated by Huma	—Not disclosedNo run-rate stated in the announcement	Huma, 16 Jul 2024Also: Bloomberg, 16 Jul 2024
11 May 2021	Closed round	Series CAnnounced as ~$130M: $100M equity + $30M credit. A further $70M equity option was agreed but is not counted (exercise not confirmed).	$100M equity (of $130M)	Leaps by Bayer, Hitachi VenturesWith: Samsung Next, Sony Innovation Fund, Unilever Ventures, HAT and others	Not disclosedNo company valuation stated by the source	—Not disclosedNo run-rate stated in the announcement	Huma via PR Newswire, 11 May 2021Also: TechCrunch, 11 May 2021
5 Nov 2019	Closed round	Series B (as Medopad)	$25M	BayerWith: NWS Holdings, Healthbox	$200M–$300M post (reported)Post-money range reported by TechCrunch	—Not disclosedNo run-rate stated in the announcement	TechCrunch, 5 Nov 2019

Total raised adds equity only ($205M). Huma itself says it has raised over $300M in total, which includes credit, strategic investments and earlier rounds not itemised here.

Amount raised in each closed round

Amounts raised (equity): no round has a single stated valuation figure.

Series BNov 2019$25M
Series CMay 2021$100M equity (of $130M)
Series DJul 2024Over $80M

Sources: Huma, Bloomberg, Huma via PR Newswire, TechCrunch. US$ billions, linear scale.

Timeline

Each round and share sale, oldest first.

5 Nov 2019 · Closed
Series B (as Medopad): $25M led by Bayer.
11 May 2021 · Closed
Series C: $100M equity (of $130M) led by Leaps by Bayer, Hitachi Ventures.
16 Jul 2024 · Closed
Series D: Over $80M.
16 May 2025 · Closed
Strategic investment (Eckuity Capital): amount not disclosed led by Eckuity Capital.

Still private: Huma has not filed for an IPO and has not been acquired. It is itself an acquirer: it bought Aluna in May 2025.

Cite this dataset

Free to quote with a link back. Copy this citation:

Huma Funding Rounds & Valuation History. Private Valuation & Funding Round Tracker, GrowthNavigateFunding.net, updated 13 Nov 2026. https://growthnavigatefunding.net/funding/huma/

Download the data

The same 4 rows as the table: numeric US$ columns, empty cells where a figure is not disclosed, and a source URL for every row.

File: huma-rounds.csv (UTF-8, comma-separated)
Stable URL: https://growthnavigatefunding.net/wp-content/uploads/2026/11/huma-rounds.csv
Columns: id, date, date_precision, status, transaction_type, round, amount_usd_low, amount_usd_high, lead_or_buyer, co_leads, valuation_usd_low, valuation_usd_high, valuation_basis, valuation_to_run_rate_multiple, multiple_bound, multiple_basis, step_up_vs_prior_closed, price_per_share_usd_low, price_per_share_usd_high, shares, source, source_url, other_source_urls, notes, last_updated
Updated: 13 Nov 2026 (IST)

⬇ Download CSV

Methodology & status definitions

How each row is labelled and calculated.

Closed round

A primary round announced by the company or confirmed in the press, bringing new money to the company.

Valuation ÷ run-rate

Post-money valuation ÷ the run-rate the company stated in that announcement (GNF calc.). Where the run-rate is “crossed” or “over” a figure, the multiple is shown as “under X×”. No row qualifies here unless shown, so no multiple is invented.

What is not a separate row

Seed and Series A as Medopad; the $30M credit in 2021; the optional $70M Series C extension; Eckuity amount (undisclosed); Huma’s own investments (e.g. ViferaXS, 2026).

Updates & corrections

This page stays at one address and is updated in place; the “Last updated” date above drives the citation and the dataset metadata. Corrections: hello@growthnavigatefunding.net. Informational only; not investment advice.

Changelog

13 Nov 2026: Dataset first compiled (batch 4, not yet published).

Huma Funding Rounds & Valuation History (2019–2025)